8.30 Coffee & Refreshments

9:00 am Chair’s Opening Remarks

  • Gopi Shanker Director, Head of Psychiatry, Novartis Institutes for Biomedical Research

9:10 am Exploring Mechanistic Approaches to Treating Neuropsychiatric Disorders such as Depression, Autism & Cognitive Impairment


• Analyzing preclinical data for ANAVEX1-41
• Discovering the links between compound classes and how we can exploit these

9:40 am Leveraging Informatics & Digital Technologies for Precision & Predictive Neuropsychiatric Diseases

  • Vaibhav Narayan Vice President, Data Science, Neuroscience Therapeutic Area, Janssen R&D


• Implementing wearable sensors and smartphones for early diagnosis and disease course monitoring
• Developing novel ‘point-of-need’ tools and technologies for management of adherence and prediction of relapse in patients with schizophrenia

10:10 am Exploring Boehringer-Ingelheim’s Commitment to Bringing First-inClass Medicines to Neuropsychiatric Patients

  • Christian Thomsen Global Head, CNS Business Development & Licensing, Boehringer Ingelheim


• A focus on innovative approaches to modulate maladaptive neurocircuits and
neural network activity across symptom domains
• Key indications include Schizophrenia, Major Depressive disorders and Impulsivity

10.40 Morning Refreshments & Networking Break

Deep Dive into Approaches for Treating Post Traumatic Stress Disorder, a Truly Unmet Medical Need

11:20 am Pioneering Novel Therapeutic Approaches to Address PTSD


• Exploring NYX-783: an NMDA receptor modulating small molecule in Phase 2 clinical development as a therapy for post-traumatic stress disorder
• Development of drugs that facilitate a more rapid extinction of a trauma response, acting on the underlying learning and memory dysfunction that exists in PTSD
• How NYX-783 has demonstrated robust and long-lasting effects in preclinical models of depression, learning, and fear extinction

11:50 am BNC210: A Negative Allosteric Modulator of Alpha7 Nicotinic Acetylcholine Receptor in Development for the Treatment of Anxiety, Depression & Post Traumatic Stress Disorder


• Why is this novel target relevant for treatment of anxiety, depression and PTSD?
• Clinical data demonstrating target engagement from EEG studies and proof-ofbiology in healthy subjects
• Combination of imaging and behavioral studies in GAD patients comparing with lorazepam
• PTSD pharmacometric analysis
• Defining the path forward

12:20 pm Developing a PTSD Therapeutic – Phase 3 Clinical Development


  • Targeting disturbed sleep in PTSD to facilitate recovery
  • Role of time-since-trauma in treatment responsiveness
  • Trimodal mechanism of action of cyclobenzaprine; enhancement by dynamic diurnal pharmacokinetic delivery

12.50 Networking Lunch

Deep Dive into Schizophrenia Drug Development

1:50 pm Investigating How Altered C4 Expression Contributes Directly to Schizophrenia Pathogenesis


  • Exploring how increased expression of schizophrenia associated gene C4 leads to hypoconnectivity of prefrontal cortex and reduced social interaction
  • Developing a transgenic mouse model to establish more translation approaches to study how we can revere schizophrenia associated phenotypes
  • Showing schizophrenia as a neurodevelopmental disorder and dissecting how the developmental trajectory of the brain changes

Deep Dive into Clinical Case Studies for Schizophrenia Candidates

2:20 pm Emergence of the Next Generation of Anti-Psychotics

  • Steve Paul CEO and Chairman, Karuna Therapeutics, Inc


• Diving into KarXT, a novel medicine for treating psychosis
• Preferentially targeting and stimulating muscarinic receptors in the central nervous system and leaving those in the peripheral tissues unaffected
• Sharing clinical data and outlining the steps involved in initiating the Phase III trial

2:50 pm Schizophrenia, A New Treatment Option for Patients

  • Sharon Mates Chairman, President & CEO, Intra-Cellular Therapies, Inc.


• Efficacy and safety of a new antipsychotic

15:20 Afternoon Refreshments

Innovative Approaches to Understanding Psychiatric Disorders to Drive More Clinically Effective Drugs

3:50 pm Harnessing the Gut-Brain Axis to Develop Therapeutics for Neurodevelopmental Disorders


  • Overview of mechanisms of action involved in treating neurological disorders via the gut-brain axis
  • Neurodevelopmental studies, advancing AB-2004 to help a significantly underserved ASD population
  • Examining exploratory endpoints including changes in bacterial metabolite levels, GI function, gut microbiome and behavior
  • Building a unique class of gut-targeted programs for neuropsychiatric and
    neurodegenerative diseases

4:20 pm Harnessing the Gut-Brain Axis to Develop Therapeutics for Neurodevelopmental Disorders

  • Giulio Maria Pasinetti Saunders Family Chair & Professor of Neurology, Psychiatry & Neuroscience,Geriatrics & Adult Development, Icahn School of Medicine, Mount Sinai


  • Discuss evidence highlighting how psychological stress through inflammasome complexes integrates signals in innate immune cells (microglia) to promote neuroinflammation
  • Delving into the relationship between inflammatory responses and stress induced psychiatric disorders such as major depressive disorders (MDD)
  • Bioactive dietary prebiotic metabolites that influence innate immune crosstalk, promoting resilience to depression and anxiety by synbiotic treatments
  • Testing synbiotic biomarkers in the human model Trier Social Stress Test (TSST)

4:50 pm Chair’s Closing Remarks

  • Gopi Shanker Director, Head of Psychiatry, Novartis Institutes for Biomedical Research

17:00 Post Event Networking